跳转至内容
Merck
CN

SML3509

F13714

≥95% (HPLC)

别名:

(3-Chloro-4-fluorophenyl)-(4-fluoro-4-{[(5-methyl-6-methylaminopyridin-2-ylmethyl)amino]methyl}piperidin-1-yl)methanone, 1-(3-Chloro-4-fluorobenzoyl)-4-fluoro-N-[[5-methyl-6-(methylamino)-2-pyridinyl]methyl]-4-piperidinemethanamine, F 13714, F13714

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C21H25ClF2N4O
化学文摘社编号:
分子量:
422.90
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

Biochem/physiol Actions

F13714 is an orally active, high-affinity, potent, biased serotonin receptor 5-HT1A agonist (pKi = 10.12 against 0.2 nM (±)-8-OH-DPAT binding to rat cortex tissue). F13714 inhibits 100 μM forskolin-induced cAMP accumulation in human 5-HT1A-expressing HeLa cells (pIC50 = 8.67) and displays antidepressant efficacy in vivo (ED50 = 0.05 mg/kg p.o., Emax >80%; rat forced swimming). F13714 and F15599 display differential biased agonism and, when administerd in vivo, F13714 preferentially activates raphe-located autoreceptors, while F15599 preferentially activates post-synaptic heteroreceptors.
Orally active, high-affinity, potent, biased serotonin receptor 5-HT1A agonist with a differential mode of action as F15599 in vitro and in vivo.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Adrian Newman-Tancredi et al.
Neurochemical research, 43(5), 1035-1046 (2018-03-25)
Peak-dose dyskinesia is associated with the dramatic increase in striatal dopamine levels that follows L-DOPA administration. The 'false neurotransmitter' hypothesis postulates that the latter is likely due to an aberrant processing of L-DOPA by serotonergic neurons. In keeping with this
H Iderberg et al.
Neuropharmacology, 93, 52-67 (2015-02-04)
Serotonin 5-HT1A receptor agonists reduce L-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease (PD). Here, we compared the effects of novel 5-HT1A receptor 'biased agonists' on LID in hemiparkinsonian rats. F13714 preferentially activates pre-synaptic 5-HT1A autoreceptors. F15599 preferentially activates
W Koek et al.
European journal of pharmacology, 420(2-3), 103-112 (2001-06-16)
To examine further the hypothesis that the magnitude of the intrinsic activity of agonists at 5-HT1A receptors determines the magnitude of their psychotropic activity, we studied the relationship between the maximal receptor activation produced by various 5-HT1A receptor ligands and
N P van Goethem et al.
British journal of pharmacology, 172(10), 2532-2543 (2015-01-13)
Pattern separation, that is, the formation of distinct representations from similar inputs, is an important hippocampal process implicated in cognitive domains like episodic memory. A deficit in pattern separation could lead to memory impairments in several psychiatric and neurological disorders.
Sietse F de Boer et al.
Psychopharmacology, 233(6), 937-947 (2015-12-24)
The serotonin (5-HT) deficiency hypothesis of aggression is being seriously challenged by pharmacological data showing robust anti-aggressive effects of 5-HT1A receptor agonists in dose ranges that concomitantly inhibit 5-HT neurotransmission. Hence, an adequate interpretation of the role of 5-HT activity

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持